IUO in the News
Media Coverage
UCLA Health Continues to Transform Cancer Care
As we celebrate the 100-year milestone of UCLA, we'd like to acknowledge the contributions of UCLA Health Jonsson Comprehensive Cancer Center. Since its inception, the center has dedicated itself to providing the best in leading-edge and traditional cancer treatments and expertly guiding the next generation of medical research. Transformative research work from the IUO co-Director Arie Belldegrun and IUO Board Member Dennis Slamon was highlighted. UCLA Magazine >
- Arie Belldegrun, MD developed the first FDA approved CAR-T cell therapy.
- Dennis Slamon, MD, PhD (pictured right) led to the development of a breast cancer drug that has saved thousands of women's lives.
November 12, 2024
Combination approach shows promise for treating rare, aggressive cancers - Dr. Arnold Chin, professor of urology at the David Geffen School of Medicine at UCLA, is a senior author of a study that shows combining immunotherapy with chemotherapy is safe and effective for people with advanced small cell cancers in the bladder and prostate. Learn more at the UCLA Health Newsroom.
Additional coverage: Drug Discovery World, Science Daily, Health Medicine Network, Medical Xpress, The ASCO Post, Inside Precision Medicine
October 29, 2024
Doctor describes first robotic high intensity ultrasound procedures with Focal One, Unfold AI - Dr. Wayne Brisbane, assistant professor of urology at the David Geffen School of Medicine at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center, is interviewed for .
October 22, 2024
UCLA efforts to provide prostate cancer treatment in the community gets $6 million boost - The IMPACT program provides free, comprehensive prostate cancer treatment for low-income California residents. Learn more at the .
Additional coverage: ,
October 3, 2024
New imaging technique accurately detects aggressive kidney cancer – Dr. Brian Shuch, director of the Kidney Cancer Program and the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research at UCLA, led UCLA Investigators to find the level of accuracy of the non-invasive method could lead to earlier diagnoses, better patient outcomes and help reduce overtreatment. An additional investigator was Dr. Allan Pantuck, professor of urology and vice chair of academic affairs for UCLA Urology. Learn more at the .
Additional coverage: Health Day, Economic Times Healthworld
September 25, 2024
Study helps predict how long it will take for testosterone to return to normal after prostate cancer treatment - UCLA Urology’s Drs. Robert Reiter, Sriram Eleswarapu and Matthew Rettig are authors on a study that sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy for prostate cancer, providing key insights for optimizing patient care. Learn more at the UCLA Health Newsroom.
September 17, 2024
ANKTIVA Boosts BCG for bladder cancer - Dr. Karim Chamie, associate professor of urology at the David Geffen School of Medicine at UCLA, provides expert commentary to .
August 1, 2024
Dr. Wayne Brisbane discusses new prostate cancer study – Dr. Wayne Brisbane, assistant professor of urology at the David Geffen School of Medicine at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center, provides expert commentary to KTLA 5.
Additional coverage: KTLA Video
July 25, 2024
Study identifies unique treatment preference profiles in men with prostate cancer – Dr. Christopher Saigal, professor and executive vice chair of urology at the David Geffen School of Medicine at UCLA and Dr. Jonathan Bergman, assistant professor of urology at the David Geffen School of Medicine at UCLA are authors of a study that holds promise for more personalized and effective prostate cancer care. Learn more at the UCLA Health Newsroom.
Additional coverage: Medical Xpress, ScienMag, Urology Times
July 2024
Dr. Robert Reiter, Bing professor of urologic oncology, chief of the division of urologic oncology, and director of UCLA's prostate cancer program, and Dr. Nicholas Donin, urologist and urologic oncologist at the David Geffen School of Medicine at UCLA, were included in Newsweek’s 2024 America’s Best Prostate Cancer Oncologists list. Learn more at News Week(Link is external) (Link opens in new window).
July 16, 2024
Dr. Tanya Stoyanova receives $1.8 million to reveal new treatment strategies for advanced prostate cancer - Dr. Tanya Stoyanova, associate professor of molecular and medical pharmacology and urology at the David Geffen School of Medicine at UCLA, was awarded a $1.8 million grant from the National Cancer Institute to identify new drivers and test new therapeutic strategies for advanced treatment-resistant prostate cancer. Dr. Arnold Chin, associate professor of urology at the David Geffen School of Medicine at UCLA, is a co-investigator. Learn more at the UCLA Health Newsroom(Link opens in new window).
July 16, 2024
Inside Pirates utilityman Connor Joe's journey from cancer survivor to a 'grateful' father - Dr. Mark Litwin, professor and chair of urology at the David Geffen School of Medicine at UCLA, is mentioned in cancer survivor's experience. Learn more at the Pittsburgh Post-Gazette(Link is external) (Link opens in new window).
July 15, 2024
Cancer researchers receive grant to combat aggressive kidney cancer - Dr. Heather Christofk, director of Basic and Translational Research at the UCLA Health Jonsson Comprehensive Cancer Center, and Dr. Brian Shuch, director of the Kidney Cancer Program and the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research at UCLA, have received an $800,000 grant from the V Foundation to find new ways to treat and prevent a severe form of kidney cancer associated with a hereditary syndrome caused by mutations in the fumarate hydratase (FH) gene. Learn more at the UCLA Health Newsroom(Link opens in new window).
Additional coverage: Sciencenewsnet(Link is external) (Link opens in new window), News-Medical
July 3, 2024
Radiation oncologists awarded $1.8 million grant to advance personalized cancer therapy - Dr. Amar Kishan, executive vice chair of radiation oncology at the David Geffen School of Medicine at UCLA, is leading the team’s efforts in validating and leveraging biomarkers that can predict which patients will experience harmful side effects from radiation therapy. Learn more at the UCLA Health Newsroom(Link opens in new window).
July 1, 2024
Transforming prostate cancer care through personalized medicine - Dr. Adam Weiner, urologic oncology fellow at UCLA Health, is interviewed by Targeted Oncology(Link is external) (Link opens in new window).
June 24, 2024
Meet the founders of the California Institute for Immunology and Immunotherapy - Dr. Arie Belldegrun, professor of urologic oncology at the David Geffen School of Medicine at UCLA and IUO co-Director, discusses how the new institute will support scientific discoveries and groundbreaking medical treatments. Learn more at the UCLA Health Newsroom(Link opens in new window).
June 12, 2024
AI model may yield better outcomes for prostate cancer - Dr. Wayne Brisbane, assistant professor of urology at the David Geffen School of Medicine at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center, discusses using AI assistance for identifying cancerous tissue was 45 times more accurate than doctors' measurments alone. Learn more at the UCLA Health Newsroom.
Additional coverage: Scienmag, Medical Xpress, AZRobotics, Fox News, Quartz, New York Post, HeadTopics
June 11, 2024
Scientists accurately measure cancer evolution - Dr. Paul Boutrous, professor of urology and human genetics at the David Geffen School of Medicine at UCLA and director of cancer data science at the UCLA Health Jonsson Comprehensive Cancer Center, provides expert commentary to Scienmag.
May 20, 2024
What does the US FDA approval of Anktiva signify for bladder cancer care? – Dr. Karim Chamie, associate professor of urology at the David Geffen School of Medicine at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center, provides expert commentary to Oncology Central.
May 14, 2024
OncLive’s April roundup of key FDA decisions in oncology – Dr. Karim Chamie, associate professor of urology at the David Geffen School of Medicine at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center, provides expert commentary to OncLive.
May 3, 2024
Dr. John Lee receives grants from Department of Defense – Dr. John Lee, associate professor at the UCLA David Geffen School of Medicine at UCLA, receives grants from Department of Defense. Learn more at the UCLA Health Newsroom.
April 19, 2024
Salvage RT after prostatectomy prevails in long-term comparison with adjuvant RT – Dr. Amar Kishan, assistant professor and chief of genitourinary oncology service at the David Geffen School of Medicine at UCLA, provides expert commentary to MedPageToday.
April 1, 2024
Cancer researcher elected to American Society for Clinical Investigation - Dr. John Lee, associate assistant professor in residence of hematology/oncology in the David Geffen School of Medicine at UCLA, has been elected as a member of the American Society for Clinical Investigation, one of the oldest and most esteemed nonprofit honor societies of physician-scientists. Learn more at the UCLA Health Newsroom.
March 27, 2024
SIR 2024: Study finds ultrasound ablation to be a precise, effective treatment for prostate cancer - Coverage of study led by Dr. Steven Raman, professor of radiology, urology and surgery at the David Geffen School of Medicine at UCLA and member, UCLA Health Jonsson Comprehensive Cancer Center at Health Imagine News.
Additional Coverage: Yahoo! News, Newsmax, MedicineNet, Health Day, United Press International, eCancer, Easy Health Options
March 18, 2024
Attacking metastatic prostate cancer early with combination treatment approach improves outcomes in preliminary study – Dr. Amar Kishan, assistant professor and chief of genitourinary oncology service at UCLA and member of the UCLA Jonsson Comprehensive Cancer Center, discusses a novel treatment approach that combines potent hormone therapy with metastasis-directed stereotactic body radiation therapy to treat metastatic prostate cancer. Learn more at the UCLA Health Newsroom.
Additional Coverage: Medical Xpress, The ASCO Post
March 12, 2024
Dr. Calais on controversies in the treatment of patients with prostate cancer – Dr. Jeremie Calais, assistant professor of nuclear medicine and theranostics in the department of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center, provides expert commentary to OncLive.
March 11, 2024
Higher prostate cancer rates seen in black men, but advanced cases similar to white men – Dr. Amar Kishan, assistant professor and chief of genitourinary oncology service at UCLA and member of the UCLA Jonsson Comprehensive Cancer Center, provides expert commentary to MDEdge.
March 7, 2024
Unfold AI demonstrates utility for prostate cancer treatment planning in real-world case – Dr. Wayne Brisbane, assistant professor of urology at the David Geffen School of Medicine at UCLA, provides expert commentary to Urology Times.